No­var­tis re­it­er­ates its faith in Eylea ri­val Beovu; An­ti-NGF drug from Lil­ly, Pfiz­er is ac­cept­ed for FDA re­view

→ Last month, the Chica­go-based Amer­i­can So­ci­ety of Reti­na Spe­cial­ists high­light­ed 14 cas­es of reti­nal vas­culi­tis that have re­cent­ly emerged with Re­gen­eron’s Eylea ri­val — No­var­tis’ Beovu. An­a­lysts al­so iden­ti­fied 36 se­ri­ous cas­es re­port­ed to the FDA Ad­verse Event Re­port­ing Sys­tem, with 2 cas­es of vas­culi­tis, 6 cas­es of blind­ness and 4 cas­es of eye in­flam­ma­tion. No­var­tis, which has pre­vi­ous­ly said it had en­gaged an ex­ter­nal safe­ty re­view com­mit­tee to look in­to these post-mar­ket­ing safe­ty con­cerns, is­sued a press re­lease on Mon­day back­ing the drug, say­ing it be­lieves the in­ci­dence of these events is con­sis­tent with the med­i­cine’s pack­age in­sert.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.